📰 Efficacy Endpoints News
Efficacy Endpoints News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Efficacy Endpoints. Real-time updates on events, politics, business and more.
May 26, 2023
/PRNewswire/ -- Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: On Thursday, the FDA issued...
May 2, 2023
/PRNewswire/ -- CSL Vifor today announced topline primary efficacy results from the pivotal Phase 3 DUPLEX Study of sparsentan, a Dual Endothelin Angiotensin...
May 2, 2023
The DUPLEX Study did not achieve the primary efficacy eGFR slope endpoint over 108 weeks of treatment Secondary and topline exploratory endpoints trended favorably for sparsentan Treatment
May 1, 2023
The DUPLEX Study did not achieve the primary efficacy eGFR slope endpoint over 108 weeks of treatment Secondary and topline exploratory endpoints trended favorably for sparsentan Treatment with... | May 1, 2023
May 1, 2023
The DUPLEX Study did not achieve the primary efficacy eGFR slope endpoint over 108 weeks of treatment Secondary and topline exploratory endpoints trended...
January 25, 2023
Cassava Sciences, Inc. announced positive top-line Phase 2 results for simufilam, its oral drug candidate for Alzheimers disease dementia. This was an open-label safety study with exploratory... | January 25, 2023
November 8, 2022
/PRNewswire/ -- UCB, a global biopharmaceutical company, today announced that it will present 15 abstracts across its rheumatology portfolio at ACR Convergence...
November 8, 2022
/PRNewswire/ -- UCB, a global biopharmaceutical company, today announced that it will present 15 abstracts across its rheumatology portfolio at ACR Convergence...
March 17, 2021
Share this article Share this article INDIANAPOLIS, March 17, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced patient-reported outcomes (PRO) for the investigational use of Verzenio ® (abemaciclib) in combination with standard adjuvant endocrine therapy (ET) for the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) high risk early breast cancer (EBC). The PRO analysis included patients in both arms of the study and m...
February 23, 2021
Synthetic mRNA Covid vaccines: A Risk-Benefit Analysis Published: February 23, 2021 Amidst the plethora of Covid-related issues, the Covid injections are the most imminent. Two formulations have received interim approval from the FDA, and Health Canada: Pfizer/BioNtech and Moderna. Both these injections are employing the same technology, synthetic gene therapy (SGT), which is being dispensed to the populace for the first time in human history. Medications are given to sick people to treat disea...